VIP which is used to treat CIRS/mold and PostTreatment Lyme Syndrome is facing removal by the FDA pending another 54 day comment period. No serious adverse events have been reported, only mild occasional side effects. The reason for removing it from the Bulk List is lack of larger controlled trials and also the fact they have not seen every study including the Genie dna/rna data supporting it’s use. Several further small studies, yet to be published, have not reached the literature yet including our PostLyme fatigue study.
For those interested in saving VIP or are someone where VIP helped themselves or a loved one, please read below
Please also see SurvivingMold.com homepage and information from Hopkinton Drug